Abbott Laboratories showcases robust financial performance with a notable increase in net earnings. Strategic acquisitions and product launches strengthen the company's market presence.

Marie Thibault, an analyst from BTIG, reiterated the Buy rating on Abbott Laboratories (ABT – Research Report). The associated price ...

Oppenheimer analyst Suraj Kalia maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of ...

A year later, the Abbott Diagnostics Division was formed to bring together the company's diagnostic products and services. "In 1946, Abbott became the first pharmaceutical company to have a ...

A jury found Abbott Laboratories and Mead Johnson ... the death of a premature baby that was fed its Enfamil Premature 24 product. Nearly 1,000 such lawsuits are pending against the two companies.

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...

Nov 1 (Reuters) - Abbott Laboratories (ABT.N), opens new tab shares rose nearly 5% before the bell on Friday, after a jury cleared the company and a Reckitt unit of liability in a lawsuit over ...

Abbott Laboratories and a unit of Reckitt Benckiser ... Officer Robert Ford has said in the past he’s “hopeful” the product can stay on the market. The trial, which lasted more than a ...

They’re at the center of a legal battle with the makers of specialized formulas for preterm infants — north suburban-based Abbott Laboratories ... cow’s-milk based products for preterm ...

Its top products include Pedialyte, Similac, BinaxNOW, Ensure, and Glucerna. In its strong Q3 earnings report, Abbott Laboratories (NYSE:ABT) exceeded both revenue and EPS expectations ...